Potential Risk of Radiotherapy on Fertility among Male Cancer Survivors
Ali Hosni*, Seham Elsayed Abd-Alkhalek, Mona Foda and Iman Awad
Department of Clinical Oncology, Mansoura University, Egypt
Submission: April 18, 2015; Published: April 25, 2016
*Corresponding author: Dr. Ali Hosni, Princess Margaret Cancer Centre, 610 University Ave, Toronto, Ontario, Canada, M5G 2M9, Tel: (+1) 647-895-1225; Fax: (+1) 416-946-4571; Email: email@example.com; firstname.lastname@example.org
How to cite this article: Ali H, Seham Elsayed A-A, Mona F, Iman A. Potential Risk of Radiotherapy on Fertility among Male Cancer Survivors. Canc Therapy & Oncol Int J. 2016; 1(4): 555566. DOI. 10.19080/CTOIJ.2016.01.555566. DOI: 10.19080/CTOIJ.2016.01.555566
The potential impact of radiotherapy on male fertility depends mainly on the total radiotherapy dose, tumor location, treatment volume, fractionation schedule, pre-treatment fertility status, and post-treatment survival of type-A spermatogonia.
Very low doses of direct testicular radiation could cause damage to the germinal epithelium. Doses above 0.8Gy result in azoospermia and doses below 0.8Gy give rise to oligospermia, with complete recovery (return to pre-irradiation sperm concentration), within 9–18 months following 1Gy or less, 30 months for 2–3Gy and 5 years or more for doses of 4Gy and above.
Leydig cells are more resistant to damage from radiotherapy than the germinal epithelium. Direct testicular irradiation of 20Gy, in 10 fractions, could increase the LH levels, with a decrease in serum testosterone level.
Scattered testicular irradiation is more common. Unlike the majority of normal tissues, radiation doses to the germinal epithelium of the testis given in fractionated courses cause more gonadal damage than single doses. scattered testicular doses of 0.2-0.7, 0.7-1.2, and more than 1.2Gy can cause transient oligospermia, transient azoospermia and prolonged azoospermia respectively. Leydig cell function is usually preserved with scattered doses up to 20Gy in prepubertal boys and 30Gy in sexually mature men.
If the hypothalamic-pituitary axis falls within the radiation fields, the patient is at risk of developing hypopituitarism with subsequent long-term gonadotrophin deficiency in 30-60% of cases receiving high dose radiation (50-70Gy) as in pituitary tumor and nasopharyngeal carcinoma.
Diagnosis of cancer is a life crisis for any person. Its impact varies with the type of cancer, treatment prospects, physical, emotional, and social resources of the patient. Younger persons face an additional potential loss of reproductive function and the opportunity to have children .
Infertility is recognized as the inability to conceive after 1 year or more of unprotected intercourse during the fertile phase of the menstrual cycle. The degree and persistence of gonadal damage following radiotherapy depends on the total dose, treated volume, combination regimens, fractionation schedule, fertility status before treatment and survival of type-A spermatogonia after treatment .
The testis consists of the seminiferous (or germinal) epithelium, arranged in tubules, and endocrine components (testosterone-producing Leydig cells) in the interstitial region between the tubules. The seminiferous tubules contain the germ cells, which consist of stem and differentiating spermatogonia, spermatocytes, spermatids and sperms, and the Sertoli cells, which support and regulate germ cell differentiation .
Shalet et al.  observed similar results in adults treated
with high dose (30Gy) testicular irradiation following unilateral
orchidectomy. Serum testosterone levels were significantly
reduced and LH levels significantly increased compared with
a control group who had undergone unilateral orchidectomy
without subsequent radiotherapy. .
Testicular damage is commonly caused by scattered
radiation directed to adjacent tissues to the testis. The possible
risk of testicular exposure to scattered doses is 0.4 – 18.7 % of
the administered dose even with the use of protective gonadal
shielding . This may occur in external beam radiotherapy
(EBRT) for pelvic organs cancer (as colorectal, bladder and
prostate cancer), pelvic lymph nodes (LN) as in cases of
lymphoma and seminoma, adjacent soft tissue tumors (as soft
tissue sarcoma in thigh), adjacent bony cancers (as metastases
in pelvic bone), or rarely in brachytherapy for prostate cancer.
The fractionation regimen potentially affects the radiationinduced
testicular dysfunction. Whereas in all other organ
systems, fractionation of radiation reduces the damage,
radiation doses to the germinal epithelium of the testis given
in long fractionated courses cause more gonadal damage than
single doses .
Testicular doses of less than 0.2Gy had no significant effect
on sperm counts, whilst doses between 0.2 and 0.7 Gy caused
a transient reduction in sperm concentration, with a return to
normal values within 12–24 months. Doses more than 0.7 Gy
cause transient azoospermia and doses more than 1.2 Gy cause
prolonged azoospermia .
Assessment of semen quality parameters in four men treated
for prostate cancer with brachytherapy revealed no change in
sperm concentration or motility at the 6-month post-treatment,
and 3 of the 4 men were able to initiate pregnancies . The
scattered radiation dose with brachytherapy is typically less
than 0.2 Gy.
Kinsella et al.  published data concerning 17 patients who
had received low-dose scattered irradiation during treatment
of Hodgkin disease (HD) with follow up from 3 to 7 years after
completion of radiation therapy. Testicular doses between 0.2
and 0.7 Gy caused a transient dose dependent reduction in
sperm concentration, with a return to normal values within 12–
In a study of 10 patients who received a testicular dose
of radiation of 1.2–3 Gy, in 14–26 fractions, during inverted
Y-inguinal field irradiation for HD. All patients were azoospermic following treatment and recovery was not seen in a single
patient despite follow-up of over 15 months in four patients and
up to 40 months in one . An update of these data revealed
no recovery of spermatogenesis in patients receiving doses of
1.4–2.6 Gy after 17–43 months follow up, but a return of fertility
in the two patients with testicular radiation doses of 1.2 Gy,
suggesting that this may represent a threshold for permanent
testicular damage .
Significant rises in LH with no change in testosterone level
have been demonstrated with fractionated dose radiation of
above 2Gy. However, fractionated radiation appears to produce
tubular damage similar to that seen with single doses. Leydig
cell function is usually preserved with doses up to 20Gy in
prepubertal boys and 30Gy in sexually mature men .
Cranial radiation is used to manage pituitary tumours,
skull base and brain tumours, head and neck cancer, and for
the prophylaxis of intracranial disease in patients with ALL. If
the hypothalamic-pituitary axis falls within the radiation fields,
the patient is at risk of developing hypopituitarism. The effect
of radiation is determined by the dose and the time that has
elapsed since treatment. Classically, growth hormone (GH) is the
most sensitive of the anterior pituitary hormones to irradiation,
followed by gonadotrophins .
Gonadotrophin deficiency occurs infrequently and is usually
a long-term complication following a minimum radiation dose
of 30Gy. A much higher incidence of gonadotrophin deficiency
(30-60% after 10 years) occur after more intensive irradiation
(>70Gy) used for nasopharyngeal carcinomas and tumours of
the skull base and following conventional irradiation (50 Gy) for
pituitary tumours .
Radiation-induced anterior pituitary hormone deficiencies
are irreversible and progressive. Regular testing is mandatory to
ensure early diagnosis and early hormone replacement therapy
in adults to preserve sexual function and improve the quality of
In the past, the primary goal of cancer therapy (i.e., survival)
tended to overshadow survivorship considerations. However,
with recent advances in oncology, survival rates are increasing,
and therefore, issues affecting long-term cancer survivors
especially fertility preservation become more important and
more widely recognized for better quality of life for cancer
Radiation oncologists have the responsibility to inform
patients about the potential risk of radiotherapy on fertility
and methods of fertility preservation before the start of cancer treatment. Moreover, in cancer patients who are interested in maintaining their fertility, every possible effort should be taken
to avoid potential impact of radiotherapy on gonadal function,
and assessment of pre-treatment fertility is important for
selection of the optimum method for fertility preservation.
The testis is one of the most radiosensitive tissues. Direct
testicular irradiation ( such as testicular exposure in whole
body irradiation as in cases of BMT), and scattered radiation
(directed to surrounding primary or metastatic cancer) may
cause damage to both germinal epithelium and Leydig cell
function. The degree and persistence of this damage following
radiotherapy depends on total dose, irradiated volume,
combination regimens, fractionation schedule, fertility status
before treatment and survival of type-A spermatogonia after
treatment. Furthermore, late gonadotrophin deficiency may
occur as a result of hypothalamo-pituitary irradiation.